Market closed
Vaxart/$VXRT
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Vaxart
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Ticker
$VXRT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
109
Website
Vaxart Metrics
BasicAdvanced
$138M
Market cap
-
P/E ratio
-$0.40
EPS
0.70
Beta
-
Dividend rate
Price and volume
Market cap
$138M
Beta
0.7
52-week high
$1.54
52-week low
$0.52
Average daily volume
1.5M
Financial strength
Current ratio
0.827
Quick ratio
0.776
Long term debt to equity
25.492
Total debt to equity
33.716
Interest coverage (TTM)
-24.56%
Management effectiveness
Return on assets (TTM)
-32.91%
Return on equity (TTM)
-103.37%
Valuation
Price to revenue (TTM)
6.564
Price to book
2.02
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
-2.143
Growth
Revenue change (TTM)
303.27%
Earnings per share change (TTM)
-36.02%
3-year revenue growth (CAGR)
142.59%
3-year earnings per share growth (CAGR)
-9.54%
What the Analysts think about Vaxart
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vaxart stock.
Vaxart Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vaxart Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vaxart News
AllArticlesVideos
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
GlobeNewsWire·3 weeks ago
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vaxart stock?
Vaxart (VXRT) has a market cap of $138M as of December 26, 2024.
What is the P/E ratio for Vaxart stock?
The price to earnings (P/E) ratio for Vaxart (VXRT) stock is 0 as of December 26, 2024.
Does Vaxart stock pay dividends?
No, Vaxart (VXRT) stock does not pay dividends to its shareholders as of December 26, 2024.
When is the next Vaxart dividend payment date?
Vaxart (VXRT) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxart?
Vaxart (VXRT) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.